The PERTAIN trial was the first study to explore the efficacy of adding pertuzumab to trastuzumab and an AI, along with or without induction CT, as the first line of treatment in postmenopausal patients with HR-positive/HER2-positive metastatic or locally advanced BC [67]. The gene discussed is ERBB2; the disease is breast cancer.